Symptomatic Therapy Trials

1. Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer

      ClinicalTrials.gov Identifier:              NCT01885754      

 
Patients with lung cancer are more likely to experience cachexia, a severe debilitating disorder causing fatigue, weight loss, muscle wasting and associated with reduced physical function, increased chemotherapy toxicity and reduced survival. The study will explore muscle function, signaling pathways and its relationship to impaired functional capacity of patients with non-small-cell lung cancer(NSCLC); depending if whether they have cachexic state at diagnosis.
 
Quebec
Institut universitaire de cardiologie et de pneumologie de Québec
 

2. Body Composition Analysis for Patient With Lung Cancer Using Computed Tomography Image Analysis (BAT-SCAN)

      ClinicalTrials.gov Identifier:             NCT01887769      

 
This is a retrospective study extending over a period of 3 years conducted at the Institut universitaire de cardiologie et de pneumologie de Québec (2009-2012)., which aims to analyze body composition of patients with lung cancer at diagnosis using computed tomography (CT-Scan) image analysis.
 
Quebec 
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
 

3. Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer (TIDAL)

      ClinicalTrials.gov Identifier:             NCT01172925      

 
The feeling of shortness of breath is very common in lung cancer. It is uncomfortable for patients and upsetting for their family. Although drugs like morphine and oxygen can help some patients feel better, they don't help everybody, and they are not used in patients with early symptoms. More relief is needed for these patients. The investigators are studying a drug called tiotropium, which is used in emphysema. It is an inhaler that opens the airways to allow easier breathing. Every patient will get the drug but also a placebo, in a random (flip of a coin) order. They will get each for 2 weeks. The investigators will see if they feel better with the drug.
 
Ontario 
Juravinski Cancer Center
Hamilton 

4. A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline

      ClinicalTrials.gov Identifier:             NCT02080078      

 
This study is to determine the use of theophylline in patients with NSCLC and advanced solid malignancies and whether treatment with theophylline will help lower or diminish the side effect of diarrhea in patients taking erlotinib. Patients will be enrolled in one of two parts of the study to verify the lowest dose of theophylline that is effective and the highest dose of erlotinib that can be tolerated with theophylline. If this study shows that theophylline is able to inhibit erlotinib induced diarrhea, it will help demonstrate that patients using the tyrosine kinase inhibitor (TKIs), erlotinib, can use it effectively at higher doses without experiencing severe diarrhea.
 
Alberta 
Cross Cancer Institute
Edmonton
 

5. An Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC (CURCUMIN)

      ClinicalTrials.gov Identifier:             NCT0232193      

 
The purpose of this study is is to assess the safety and tolerability of curcumin in combination with EGFR-TKIs in selected patients with advanced non-resectable mutant EGFR NSCLC.
 
Quebec 
Peter Brojge Lung Cancer Center, Jewish General Hospital
Montreal, Quebec, H3T 1E2